Huperzine A is a natural alkaloid from Chinese club moss. It selectively inhibits acetylcholinesterase, raising brain acetylcholine. It also has NMDA modulating effects. Used as a memory supplement and in Alzheimer research. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Reversible, selective acetylcholinesterase inhibitor and non-competitive NMDA receptor antagonist of Lycopodium alkaloid origin
A sesquiterpene Lycopodium alkaloid isolated from the Chinese club moss Huperzia serrata, distinguished from the clinically marketed cholinesterase inhibitors by high AChE selectivity, concurrent non-competitive NMDA receptor antagonism, and multi-target neuroprotective activity spanning anti-oxidative, anti-apoptotic, and mitochondrial protective mechanisms.
Abstract
Huperzine A ((-)-huperzine A, HupA) is a naturally occurring sesquiterpene alkaloid of the Lycopodium class, first isolated in 1986 from the Chinese club moss Huperzia serrata (Qian Ceng Ta) by Liu and colleagues at the Shanghai Institute of Materia Medica. The compound is a potent, reversible, and highly selective inhibitor of acetylcholinesterase (AChE) with an inhibition constant (Ki) of approximately 6.2 nanomolar against the natural (-)-enantiomer and approximately 900-fold selectivity for AChE over butyrylcholinesterase (BuChE), a selectivity ratio substantially greater than that of the clinically marketed cholinesterase inhibitors donepezil, rivastigmine, and galantamine. In addition to cholinesterase inhibition, huperzine A acts as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor at the phencyclidine binding site within the ion channel pore, with a pseudo-Ki of approximately 6 micromolar against [3H]MK-801 binding and functional IC50 values of 65 to 82 micromolar in electrophysiological assays. This dual mechanism positions huperzine A as both a cholinergic enhancer and an anti-excitotoxic neuroprotectant.
Beyond these two principal targets, huperzine A exerts a suite of neuroprotective activities that are not fully explained by cholinesterase inhibition or NMDA antagonism alone. These include protection against amyloid-beta-induced oxidative injury and apoptosis in neuronal cultures, attenuation of mitochondrial dysfunction through preservation of membrane potential and cytochrome c retention, upregulation of nerve growth factor expression, promotion of non-amyloidogenic amyloid precursor protein processing via the alpha-secretase pathway, and reduction of brain iron accumulation. These multi-target activities have generated a research literature that extends from Alzheimer’s disease through vascular dementia, traumatic brain injury, organophosphate poisoning prophylaxis, myasthenia gravis, epilepsy, and age-related cognitive decline.
The clinical evidence base for huperzine A in Alzheimer’s disease encompasses over 20 randomized controlled trials conducted predominantly in China, with a combined enrollment exceeding 1,800 participants. A 2013 systematic review and meta-analysis of these trials reported statistically significant improvements in Mini-Mental State Examination scores and activities of daily living at 8, 12, and 16 weeks of treatment. A United States Phase II multicenter trial (Rafii et al. 2011) randomized 210 individuals with mild to moderate Alzheimer’s disease to placebo or huperzine A at 200 or 400 micrograms twice daily for 16 weeks; the higher dose produced a 2.27-point improvement on the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) at 11 weeks versus a 0.29-point decline on placebo in secondary analyses, though the primary efficacy analysis at 200 micrograms twice daily did not reach significance. Huperzine A has been approved in China since 1994 as a prescription medication (marketed as Shuangyiping) for Alzheimer’s disease treatment. It is not approved by the United States Food and Drug Administration, the European Medicines Agency, or other Western regulatory authorities; in Western markets it is sold as a dietary supplement or as a research-grade preparation.
Pharmacokinetics in humans are characterized by rapid oral absorption (time to peak concentration approximately 60 minutes), high oral bioavailability, wide tissue distribution including blood-brain barrier penetration, and an elimination half-life of approximately 10 to 12 hours following single oral dosing. The compound is well tolerated at standard doses of 200 to 400 micrograms twice daily; the principal adverse events are cholinergic in nature (nausea, vomiting, diarrhea, dizziness, insomnia) and occur in approximately 10 to 20 percent of treated subjects with mild to moderate severity. Animal toxicology studies demonstrate a wide therapeutic index, with no significant toxicity observed at 50 to 100 times the human therapeutic dose. This monograph reviews the chemistry, biosynthesis, and total synthesis of huperzine A; the dual-target molecular pharmacology at AChE and the NMDA receptor; the multi-target neuroprotective profile; the comprehensive human pharmacokinetic record; the clinical evidence base across Alzheimer’s disease, vascular dementia, traumatic brain injury, and cognitive enhancement indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a structured comparative assessment of five cognitive-indication compounds (donepezil, rivastigmine, galantamine, tacrine, memantine) against huperzine A on five competency standards.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.